CTI BioPharma Revenue by Segment

Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023
Product Sales	81.70M	97.92M	119.53M	120.54M	109.42M	91.82M	70.11M	54.36M
Product Sales Growth	-25.33%	6.65%	70.48%	121.76%	137.77%	155.35%	155.69%	148.64%
Charging Service	21.45M	19.75M	18.36M	17.79M	15.65M	14.12M	11.52M	8.64M
Charging Service Growth	37.06%	39.89%	59.39%	105.78%	127.88%	173.70%	139.39%	121.47%
Network Fees	8.72M	8.52M	8.16M	7.92M	7.48M	7.55M	7.03M	5.84M
Network Fees Growth	16.51%	12.82%	16.01%	35.65%	71.19%	223.30%	548.71%	712.95%
Warranty	6.43M	4.79M	4.24M	3.82M	3.26M	2.62M	2.08M	1.25M
Warranty Growth	97.27%	83.22%	104.09%	204.47%	251.08%	354.17%	486.44%	357.66%
Ride Sharing Services	4.67M	4.66M	4.39M	4.15M	3.30M	2.50M	1.96M	1.28M
Ride Sharing Services Growth	41.34%	86.65%	124.20%	223.73%	160.41%	117.15%	86.22%	33.16%
Grant and Rebate	1.70M	1.80M	867.00K	1.00M	469.00K	297.00K	333.00K	270.00K
Grant and Rebate Growth	263.33%	506.73%	160.36%	271.48%	58.45%	-26.49%	-11.44%	-16.92%
Other	1.54M	1.29M	1.38M	1.29M	1.03M	1.60M	1.33M	1.37M
Other Growth	49.61%	-19.55%	3.38%	-5.64%	-26.35%	76.91%	146.67%	193.76%

Operating Expense Breakdown

Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023
Compensation	58.67M	64.47M	64.58M	84.92M	92.67M	98.93M	101.26M	74.05M
Compensation Growth	-36.69%	-34.83%	-36.22%	14.67%	52.91%	96.40%	127.51%	72.62%
General and Administrative	31.75M	32.46M	33.02M	34.47M	35.17M	34.27M	32.32M	31.88M
General and Administrative Growth	-9.73%	-5.29%	2.16%	8.13%	26.39%	46.27%	62.42%	137.32%
Other Expenses	20.39M	19.41M	20.11M	20.07M	17.83M	18.04M	17.68M	16.90M
Other Expenses Growth	14.40%	7.56%	13.77%	18.76%	13.93%	9.21%	32.47%	61.06%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.